Immatics IMTX
NASDAQ IMTX
$6.64 +0.22 (+3.43%)
As of: Nov 11, 2026 · 10:46 AM EST

Immatics (IMTX) Accumulated Expenses (2023 - 2026)

Updated

Immatics (IMTX) reported Accumulated Expenses of $30.74 million for Q2 2026, up 80.8% from $17 million a year earlier.

Analysis

Immatics (IMTX) Accumulated Expenses (2023 - 2026) Analysis & Trends

At the end of FY2025, Immatics posted Accumulated Expenses of $21.72 million, up 97.3% from FY2024.

  • By year, Accumulated Expenses came in at $11.01 million in FY2024 (-43.3%) and $19.41 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Immatics 860.74 Mn -1.20 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 30.74 Mn
Dec 31, 2025 21.72 Mn
Jun 30, 2025 17.00 Mn
Dec 31, 2024 11.01 Mn
Dec 31, 2023 19.41 Mn
API Access

Immatics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=IMTX&period=max&api_key=YOUR_API_KEY